Drug Profile
Research programme: haemophilia A stem cell therapy - Opus Bio
Alternative Names: LG 889Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Lentigen Corporation
- Developer Expression Therapeutics; Opus Bio
- Class Stem cell therapies
- Mechanism of Action Blood coagulation factor replacements; Cell replacements; Factor X stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haemophilia A
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Haemophilia-A in USA (IV, Infusion)
- 30 Dec 2014 9167038, 9167065 - corrected organisational relationships; changed owner to opus bio.
- 14 Aug 2014 Lentigen Corporation starts operating as Opus Bio and gains certain rights to use lentiviral technology